NorthStar Medical Radioisotopes, along with Wilmette, Ill.-based Monopar Therapeautics, have partnered with IsoTherapeutics Group to develop and manufacture Radio-Immuno-Therapeutics (RITs) for the potential treatment of severe COVID-19, the company announced recently.

“We have successfully worked with IsoTherapeutics on a previous project that led to an FDA approval, and we value their expertise,” NorthStar Senior Vice President James T. Harvey said in a statement. “This is a crucial step in the development of a uPRIT for severe COVID-19.”

According to a release, IsoTherapeutics will modify Monopar’s targeted antibody, MNPR-101, by making conjugates that will allow the attachment of therapeutic radioisotopes supplied by NorthStar. This in turn will create a platform of RIT candidates to be evaluated as treatments for severe COVID-19. 

IsoTherapeutics Group is based in Angleton, Texas.